201 related articles for article (PubMed ID: 32202091)
1. Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.
Hajizadeh M; Edmonds S
Int J Health Policy Manag; 2020 Mar; 9(3):91-95. PubMed ID: 32202091
[TBL] [Abstract][Full Text] [Related]
2. Universal prescription drug coverage in Canada: Long-promised yet undelivered.
Morgan SG; Boothe K
Healthc Manage Forum; 2016 Nov; 29(6):247-254. PubMed ID: 27744279
[TBL] [Abstract][Full Text] [Related]
3. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
McLeod L; Bereza BG; Shim M; Grootendorst P
Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
[TBL] [Abstract][Full Text] [Related]
4. It Won't Be Easy: How to Make Universal Pharmacare Work in Canada.
Lewis S
Int J Health Policy Manag; 2020 Jan; 9(1):1-5. PubMed ID: 31902189
[TBL] [Abstract][Full Text] [Related]
5. National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare".
Rawson NSB
Int J Health Policy Manag; 2020 Dec; 9(12):524-527. PubMed ID: 32610769
[TBL] [Abstract][Full Text] [Related]
6. Estimated cost of universal public coverage of prescription drugs in Canada.
Morgan SG; Law M; Daw JR; Abraham L; Martin D
CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
[TBL] [Abstract][Full Text] [Related]
7. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
Daw JR; Morgan SG
Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
[TBL] [Abstract][Full Text] [Related]
8. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
Morgan SG; Li W; Yau B; Persaud N
CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
[TBL] [Abstract][Full Text] [Related]
9. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
Hanley GE; Morgan S; Barer M; Reid RJ
Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
[TBL] [Abstract][Full Text] [Related]
10. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
Hanley GE; Morgan S; Hurley J; van Doorslaer E
Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
[TBL] [Abstract][Full Text] [Related]
11. Canadian pharmacare: looking back, looking forward.
Morgan SG; Daw JR
Healthc Policy; 2012 Aug; 8(1):14-23. PubMed ID: 23968600
[TBL] [Abstract][Full Text] [Related]
12. Federal budget disappoints on universal pharmacare.
Vogel L
CMAJ; 2019 Apr; 191(14):E406-E407. PubMed ID: 30962204
[No Abstract] [Full Text] [Related]
13. Understanding the Battle for Universal Pharmacare in Canada Comment on "Universal Pharmacare in Canada".
Gagnon MA
Int J Health Policy Manag; 2021 Mar; 10(3):168-171. PubMed ID: 32610789
[TBL] [Abstract][Full Text] [Related]
14. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
Coombes ME; Morgan SG; Barer ML; Pagliccia N
Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
[TBL] [Abstract][Full Text] [Related]
15. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
Brandt J; Shearer B; Morgan SG
J Pharm Policy Pract; 2018; 11():28. PubMed ID: 30443371
[TBL] [Abstract][Full Text] [Related]
16. The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on "Pharmacare in Canada".
Acri Née Lybecker KML
Int J Health Policy Manag; 2021 Mar; 10(3):152-154. PubMed ID: 32610780
[TBL] [Abstract][Full Text] [Related]
17. The financial burden of prescription drugs for neurological conditions in Canada: Results from the National Population Health Study of Neurological Conditions.
Guilcher S; Munce S; Conklin J; Packer T; Verrier M; Marras C; Bereket T; Versnel J; Riopelle R; Jaglal S
Health Policy; 2017 Apr; 121(4):389-396. PubMed ID: 28215356
[TBL] [Abstract][Full Text] [Related]
18. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
Kennedy J; Morgan S
Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
[TBL] [Abstract][Full Text] [Related]
19. Should national pharmacare apply a value-based insurance design?
Yeung K; Morgan SG
CMAJ; 2019 Jul; 191(29):E811-E815. PubMed ID: 31332049
[No Abstract] [Full Text] [Related]
20. Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access?
Kanavos P; Gemmill-Toyama M
Int J Health Care Finance Econ; 2010 Sep; 10(3):203-18. PubMed ID: 20213234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
